fibrinolysis

By Targets:	Amino Acid Derivatives (1) Isotope-Labeled Compounds (2) PAI-1 (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (6) Inflammation/Immunology (2) Metabolic Disease (5)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101918

DS-1040 Tosylate	Others	Cardiovascular Disease
DS-1040 Tosylate is an orally active, selective inhibitor of activated *thrombin-activatable fibrinolysis* inhibitor (TAFIa) with IC₅₀*s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis* enhancer for thromboembolic diseases .

HY-B0236

6-Aminocaproic acid 1 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Others	Metabolic Disease Cancer
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-B0236A

6-Aminocaproic acid hydrochloride EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride	Others	Metabolic Disease Cancer
6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-142163

S62798

Others Cardiovascular Disease

S62798 is a selective and potent inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) with an IC₅₀ value of 6 mM.

S62798	Others	Cardiovascular Disease
S62798 is a selective and potent inhibitor of activated *thrombin activatable fibrinolysis* inhibitor (TAFIa) with an IC₅₀** value of 6 mM.

HY-105940

IQB-782	Amino Acid Derivatives	Cardiovascular Disease
IQB-782 is a cysteine derivative. IQB-782 has inhibition for *thrombin activatable fibrinolysis* inhibitor (TAFI), with an K_i**(app) of 0.14 μM. IQB-782 shows a potent mucolytic-expectorant activity .

HY-119160

TM5007	PAI-1	Inflammation/Immunology Cancer
TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC₅₀ of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .

HY-107802

Breviscapine Breviscapinun	Others	Cardiovascular Disease
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-B0236S1

6-Aminocaproic acid-d10 EACA-d₁₀; Epsilon-Amino-n-caproic Acid-d₁₀; 6-Aminohexanoic acid-d₁₀	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236S

6-Aminocaproic acid-d6 EACA-d₆; Epsilon-Amino-n-caproic acid-d₆; 6-Aminohexanoic acid-d₆	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236R

6-Aminocaproic acid (Standard) EACA(Standard); Epsilon-Amino-n-caproic Acid(Standard); 6-Aminohexanoic acid (Standard)	Others	Metabolic Disease Cancer
6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-120516

CDE-096	PAI-1	Cardiovascular Disease
CDE-096 is a potent inhibitor of PAI-1. CDE-096 prevents PAI-1 from inactivating tPA and uPA with similar potency (IC₅₀=30 and 25 nM, respectively) and is active against glycosylated PAI-1, as well as PAI-1 derived from several species (IC₅₀=19, 22 and 18 nM for murine, rat, and Porcine PAI-1, respectively) .

Cat. No.	Product Name	Target	Research Area

HY-P4269

Glycylglycylcysteine	Peptides	Cardiovascular Disease
Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a K_i of 0.99 μM and a IC₅₀ of 9.4 μM in TAFI substrate assays. TAFI is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin .

HY-P5356

H-D-Val-Leu-Lys-AFC Plasmin substrate	Peptides	Others
H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)

Cat. No.	Product Name	Target	Research Area

HY-112956

Drotrecogin alfa (activated)	Inhibitory Antibodies	Inflammation/Immunology
Drotrecogin alfa activated (DrotAA) is recombinant human activated protein C (APC). Drotrecogin alfa activated prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1β in rats. Drotrecogin alfa activated inhibits coagulation and inflammation and promotes fibrinolysis. Drotrecogin alfa activated can be used for severe sepsis reaearch .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0236

6-Aminocaproic acid 1 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-107802

Breviscapine Breviscapinun	Structural Classification Natural Products Source classification Plants Compositae Erigeron breviscapus (Vant.) Hand.-Mazz.	Others
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris .

HY-B0236R

6-Aminocaproic acid (Standard) EACA(Standard); Epsilon-Amino-n-caproic Acid(Standard); 6-Aminohexanoic acid (Standard)	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
6-Aminocaproic acid (Standard) is the analytical standard of 6-Aminocaproic acid. This product is intended for research and analytical applications. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

Cat. No.	Compare	Product Name	Species	Source

HY-P7735

	Carboxypeptidase B2/CPB2 Protein, Human (HEK293, His) rHuCarboxypeptidase B2, His; Carboxypeptidase B2; Carboxypeptidase U; Plasma Carboxypeptidase B; Thrombin-Activable fibrinolysis Inhibitor; CPB2	Human	HEK293
	Carboxypeptidase B2 Protein, Human (HEK293, His) is an approximately 47.0 kDa human carboxypeptidase B2 with a His-flag. Carboxypeptidase B2 is a enzyme belonging to the peptidase M14 family and hydrolyze C-terminal peptide bonds.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0236S

6-Aminocaproic acid-d6
6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

6-Aminocaproic acid-d6

6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236S1

6-Aminocaproic acid-d10
6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

6-Aminocaproic acid-d10

6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds